Heidelberg Pharma AG (XTER:HPHA) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Feb. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Heidelberg Pharma AG's net issuance of preferred for the three months ended in Feb. 2025 was €0.00 Mil. The number is 0, which means that Heidelberg Pharma AG has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Heidelberg Pharma AG's net issuance of preferred for the trailing twelve months (TTM) ended in Feb. 2025 was €0.00 Mil.

Heidelberg Pharma AG Net Issuance of Preferred Stock Historical Data

The historical data trend for Heidelberg Pharma AG's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Net Issuance of Preferred Stock Chart

Heidelberg Pharma AG Annual Data

Trend

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Heidelberg Pharma AG Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Heidelberg Pharma AG Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Heidelberg Pharma AG Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

0QW5:UK

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Walter Miller	Board of Directors
Dr. Georg F. Baur	Supervisory Board
Prof. Dr. Andreas Pahl	Board of Directors

Heidelberg Pharma AG Headlines

No Headlines